Incretins: Beyond type 2 diabetes

被引：9
作者：
Dandona, Paresh [1 ]
Ghanim, Husam [1 ]
Chaudhuri, Ajay [1 ]
机构：
[1] SUNY Buffalo, Diabet Endocrinol Ctr Western NY, 1000 Youngs Rd, Buffalo, NY 14221 USA
来源：
DIABETES OBESITY & METABOLISM | 2018年 / 20卷
关键词：
cardiovascular disease; diabetic nephropathy; incretins; type; 1; diabetes; weight control; DIPEPTIDYL PEPTIDASE-IV; ADDITIONAL TREATMENT; RECEPTOR AGONISTS; DOUBLE-BLIND; WEIGHT-LOSS; CARDIOVASCULAR OUTCOMES; INSULIN-TREATMENT; GLYCEMIC CONTROL; CONTROLLED-TRIAL; BLOOD-PRESSURE;
D O I：
10.1111/dom.13153
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
While the use of incretins, including GLP-1 receptor agonists and PDD-IV inhibitors, is well established in the treatment of type 2 diabetes, many other aspects of these agents are yet to be discovered and utilized for their potential clinical benefit. These include the potential role of GLP-1 receptor agonists in the induction of weight loss, blood pressure reduction, anti-inflammatory and nephro- and cardio-protective actions. Their potential benefit in type 1 diabetes is also being investigated. This review will attempt to comprehensively describe novel discoveries in the field of incretin pathophysiology and pharmacology beyond their classical role in the treatment of type 2 diabetes.
引用
收藏
页码：59 / 67
页数：9
相关论文
共 94 条
  • [1] Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial
    Ahren, Bo
    Hirsch, Irl B.
    Pieber, Thomas R.
    Mathieu, Chantal
    Gomez-Peralta, Fernando
    Hansen, Troels Krarup
    Philotheou, Areti
    Birch, Sune
    Christiansen, Erik
    Jensen, Thomas Jon
    Buse, John B.
    [J]. DIABETES CARE, 2016, 39 (10) : 1693 - 1701
  • [2] Aljada A, 2004, AM J CLIN NUTR, V79, P682
  • [3] [Anonymous], 1995, DIABETES, V44, P968
  • [4] Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
    Astrup, Arne
    Rossner, Stephan
    Van Gaal, Luc
    Rissanen, Aila
    Niskanen, Leo
    Al Hakim, Mazin
    Madsen, Jesper
    Rasmussen, Mads F.
    Lean, Michael E. J.
    [J]. LANCET, 2009, 374 (9701) : 1606 - 1616
  • [5] Biology of incretins: GLP-1 and GIP
    Baggio, Laurie L.
    Drucker, Daniel J.
    [J]. GASTROENTEROLOGY, 2007, 132 (06) : 2131 - 2157
  • [6] GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK
    Beiroa, Daniel
    Imbernon, Monica
    Gallego, Rosalia
    Senra, Ana
    Herranz, Daniel
    Villarroya, Francesc
    Serrano, Manuel
    Ferno, Johan
    Salvador, Javier
    Escalada, Javier
    Dieguez, Carlos
    Lopez, Miguel
    Fruehbeck, Gema
    Nogueiras, Ruben
    [J]. DIABETES, 2014, 63 (10) : 3346 - 3358
  • [7] CYTOTOXIC ACTION OF IL-1-BETA AGAINST PANCREATIC-ISLETS IS MEDIATED VIA NITRIC-OXIDE FORMATION AND IS INHIBITED BY N(G)-MONOMETHYL-L-ARGININE
    BERGMANN, L
    KRONCKE, KD
    SUSCHEK, C
    KOLB, H
    KOLBBACHOFERN, V
    [J]. FEBS LETTERS, 1992, 299 (01) : 103 - 106
  • [8] Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
    Bettge, Karolin
    Kahle, Melanie
    Abd El Aziz, Mirna S.
    Meier, Juris J.
    Nauck, Michael A.
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (03) : 336 - 347
  • [9] Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
    Blundell, John
    Finlayson, Graham
    Axelsen, Mads
    Flint, Anne
    Gibbons, Catherine
    Kvist, Trine
    Hjerpsted, Julie B.
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (09) : 1242 - 1251
  • [10] Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity
    Burcelin, R.
    Gourdy, P.
    [J]. OBESITY REVIEWS, 2017, 18 (01) : 86 - 98
12345678910